Select Language:
Sinovac Biotech has secured an exclusive contract to supply Oman’s national immunization program with its inactivated hepatitis A vaccine, Healive, for the fiscal year 2026-27. This agreement underscores the trust Gulf Cooperation Council countries place in the vaccine’s quality and demonstrates confidence in Sinovac’s capacity to meet global delivery and compliance standards.
This achievement marks a significant milestone for the company in expanding its presence within the Middle East and African markets. Historically, the immunization programs in Oman and other GCC nations have primarily relied on vaccines supplied by international pharmaceutical companies.
Healive is China’s first inactivated hepatitis A vaccine and was granted prequalification by the World Health Organization in 2017, making it the only hep A vaccine from China with such recognition. Oman has incorporated the hepatitis A vaccine into its immunization schedule since 2019, administering doses to children at 13 and 24 months to ensure long-lasting protection and minimize outbreak risks.
Long-term studies indicate that Healive offers effective immunity for at least 30 years. To date, Sinovac has distributed more than 130 million doses of the vaccine to nearly 50 countries and territories worldwide.
ChatGPT
Perplexity
Gemini AI
Grok AI
